ADM is expanding its Priome postbiotics portfolio with the addition of Priome Joint Health, a postbiotic Lacticaseibacillus rhamnosus NCIMB 30446. Preliminary in vitro and model organism research indicates that Priome Joint Health may support joint health, cartilage production, muscle maintenance, gut barrier function, and healthy weight management.

Research suggests that an imbalance in the gut microbiome and impaired gut barrier function can allow certain bacteria and compounds to cross the intestinal barrier, entering systemic circulation and impacting joint health. This transfer of metabolites is a potential link between the gut microbiome and joint health.

This has been shown in dogs; a study comparing healthy dogs compared to those diagnosed with hip or elbow arthritis showed measurable differences in gut microbial community composition and reduced bacterial diversity in arthritic animals.

“Joint health is among pet parents’ top concerns for their pet’s quality of life, as it can affect not only mobility but also energy, healthy aging, and activity levels,” said Mark Lotsch, global president of health and wellness at ADM. “Our postbiotic ingredient is an innovative, science-backed solution that can support wellness in a variety of pet-friendly applications, providing pet parents with several convenient and easy-to-use options in pet care.”

Since postbiotics are inanimate, they’re not reliant on cell viability; functionality is maintained throughout manufacturing and stability testing. The functionality of Priome postbiotics are validated by application scientists across a wide range of finished product formats, including powders, soft chews, baked treats, extruded treats, chews, liquids, dry kibble, and wet food. Efficacious inclusion rates don’t impact the taste or smell of these finished product types, the company reported.

“We combine deep formulation expertise with a robust portfolio of microbiome solutions, including prebiotics, probiotics, and postbiotics, to help brands bring consumer-driven pet products to market,” said James Kyffin, global director of pet and animal well-being at ADM. “From custom formulations to market-ready solutions, we enable convenient, on-trend innovations backed by clinically studied ingredients that deliver real value for today’s pet parents.”

Lacticaseibacillus rhamnosus NCIMB 30446 is an Association of American Feed Control Officials (AAFCO) accepted biotic species and ADM is a National Animal Supplement Council (NASC) preferred supplier. Other offerings in ADM’s Priome portfolio include solutions for oral care, metabolic health, gut health, mental well-being, and skin health.